CRP and peripheral arterial disease: Regrettably, blood-based protein biomarkers (e.g., inflammatory cytokines, C-reactive protein) have yet to be clinically validated for the routine screening of PAD, predict disease progression, and/or monitor the treatment responses of patients [6].